Pacific Peoples' Experiences of Cancer and Its Treatment in Aotearoa New Zealand Through Talanoa: A Qualitative Study of Samoan and Tongan Participants Healthy volunteers were recruited and underwent ...

CAR T-cell therapies have drastically changed treatment paradigms in R/R haematological malignancies since the first approval in 2017. Credit: Meletios Verras via Shutterstock. Chimeric antigen ...

CAR T-cell therapy has significantly improved outcomes for B-ALL patients, but relapse still occurs in over 50% of cases, leaving many with limited treatment options. Ongoing research aims to ...

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory or relapsed leukemia and hematologic malignancies, particularly over the past decade. Despite its ...

Kyverna Therapeutics’ CAR T-cell therapy candidate KYV-101 was deemed safe and well tolerated, and showed preliminary signs of efficacy, in people with progressive forms of multiple sclerosis ...

Astellas is to work with UK biotech Adaptimmune Therapeutics to develop allogeneic ‘off-the-shelf’ T-cell therapies for cancer. The Japanese pharma said its wholly-owned subsidiary Universal ...

The 2024 American College of Rheumatology (ACR) annual meeting spotlighted transformative advancements in cell therapies for autoimmune diseases, with chimeric antigen receptor (CAR)-T therapies ...

Poor physical performance in patients with non-Hodgkin lymphoma receiving CAR T-cell therapy was linked to worse survival and increased risk of neurotoxicity in a cohort study.

Methods Production of GM-CSF by peripheral blood (PB) and synovial fluid (SF) CD4+ T cells was assessed by ELISA and flow cytometry. In vitro CD4+ T-cell polarisation experiments were performed with T ...

What is chimeric antigen receptors T-cell therapy (CAR-T)? CAR-T – chimeric antigen receptor T-cell – therapy is specifically developed for each individual patient and involves reprogramming the ...